Medical Device and Healthcare Trends — 2026-08-03

Top 5 Headlines Today

• MFDS (South Korea): Extends clinical trial exemptions for digital medical devices from 1 to 3 years and prolongs field usage periods for generative AI-based products.
• Classys and others: Skin beauty device manufacturers face protests from traditional Korean medicine practitioner groups over sales refusals, sparking debate over pressure on medical professionals.
• FDA Deregulation: Significantly reduces regulations for wearables and low-risk AI medical devices, expanding exemptions for clinical decision support tools.
• South Korea Innovative Medical Device Designation: 45 products utilizing AI and big data were designated in 2025, a 50% increase from the previous year.
• MFDS 240-day approval path: The expedited approval system for innovative medical devices is confirmed to take effect starting June 1.

Key Corporate Developments

Classys — Escalating conflict over beauty device sales policy

• What happened: Major protest from Korean medicine practitioners after the refusal to sell flagship products like Shurink to traditional clinics.
• Implication: The conflict reveals structural industry tension between the pressure from medical interest groups and the sales strategies of manufacturers. There is a growing call for fair mediation and clear guidelines from regulatory authorities.

MFDS · Policy · Regulation

Extension of clinical trial exemptions for digital medical devices

• Details: The MFDS extended the exemption period for digital medical device clinical trials from 1 year to 3 years and simultaneously extended the field usage grace period for generative AI-based products.
• Target: All digital medical devices, particularly AI/machine learning-based Software as a Medical Device (SaMD).
• Effective date: Publicly notified on July 28, 2026.
• Industry Impact: The market entry barrier for AI-based healthcare products has been significantly lowered, expected to accelerate the entry of startups and established manufacturers into the digital health sector. Specifically, the commercialization of low-risk AI products like diagnostic aids, patient monitoring, and decision support tools is expected to speed up.

Abolition of grace periods for sales suspensions during MFDS GMP audits

• Details: Starting in 2026, the previous grace period for sales suspensions following violations of periodic GMP (Good Manufacturing Practice) audits will be completely abolished.
• Target: All medical device manufacturers and importers, especially in vitro diagnostic (IVD) manufacturers.
• Effective date: Immediate enforcement in 2026 (prior to GMP expiration).
• Industry Impact: The mandatory nature of GMP compliance has been significantly strengthened. Manufacturers must adhere perfectly to regulatory requirements within their GMP validity period or face immediate sales suspension. Upgrading quality management systems has become an essential task.

Growing trend in innovative medical device designations

• Details: In 2025, 45 medical devices applying advanced technologies such as AI, big data, and IoT were designated as innovative products.
• Target: AI diagnostic aids, wearable monitoring devices, digital therapeutics, etc.
• Effective date: Based on 2025 statistics.
• Industry Impact: As products utilizing innovative technology receive policy support like expedited approval and preferred insurance pricing, R&D investment competition between domestic MedTech startups and large manufacturers is expected to intensify.

Global MedTech Context

• FDA Wearable/AI Deregulation: The FDA’s massive reduction in regulations for low-risk wearables and AI-based clinical decision support tools is significantly expanding opportunities for Korean wearable and AI medical device manufacturers to enter the U.S. market.

• Exemption for non-medical grade wearables: By excluding data from non-medical grade wearable devices from regulation, the FDA has created an environment where Korean electronics companies like Samsung and LG can expand their health device businesses without regulatory risk.

• 2026 FDA approval trends: July's new approvals include guidewires, high-frequency ablation, and multi-port robotic surgical systems, accelerating innovation in the surgical medical device sector.

Digital Health & AI Medicine

• 3-year grace period for field use of digital medical devices: With the extension of the clinical trial exemption, the field validation period for AI/ML-based software has increased from 1 to 3 years, allowing more time for actual clinical data accumulation and model refinement.

• FDA exemption for AI/ML-based clinical decision tools: Low-risk AI clinical decision support tools are now exempt from regulation, allowing for faster development and commercialization.

Insights for Today

With the MFDS's extension of clinical trial exemptions and the FDA's deregulation of wearables and AI occurring simultaneously, an environment has been created where the global competitiveness of the Korean medical device industry could surge in the short term. Specifically, software-based products like AI diagnostic aids, remote monitoring, and digital therapeutics are seeing accelerated domestic approvals, while lowered global regulatory barriers are benefiting both startups and established MedTech firms. However, sales channel conflicts involving companies like Classys reveal a lack of regulatory transparency and insufficient communication among stakeholders, which remains a structural challenge to resolve in future policy-making.

Checkpoints for This Week

• Announcement of new product approvals following MFDS regulatory easing (within August).
• Announcements of U.S. expansion strategies by Korean companies following the FDA's wearable/AI deregulation guidelines.
• Public hearings mediated by regulatory authorities between skin beauty device companies (like Classys) and Korean medicine practitioner groups.

Reader Action Items

• Medical Device Manufacturers: Review requirements for the 3-year extension of clinical trial exemptions and establish a plan for accumulating field usage data.
• Startup Founders: Explore potential for U.S. market entry following the FDA's deregulation of low-risk AI clinical decision tools.
• Investors/M&A Personnel: Identify funding and acquisition opportunities for startups with innovative medical devices eligible for MFDS expedited approval.